BioScience Trends. 2024;18(3):224-232. (DOI: 10.5582/bst.2024.01156)

Trends in the treatment of advanced pancreatic cancer

Momose H, Kudo S, Yoshida T, Hasui N, Matsuki R, Kogure M, Sakamoto Y


Pancreatic cancer (PC) has the poorest prognosis among digestive cancers; only 15-20% of cases are resectable at diagnosis. This review explores multidisciplinary treatments for advanced PC, emphasizing resectability classification and treatment strategies. For locally advanced unresectable PC, systemic chemotherapy using modified FOLFIRINOX and gemcitabine with albumin-bound paclitaxel is standard, while the role of chemoradiation is debated. Induction chemotherapy followed by chemoradiation may be a promising therapy. Conversion surgery after initial chemotherapy or chemoradiotherapy offers favorable survival, however criteria for conversion need further refinements. For metastatic PC, clinical trials using immune checkpoint inhibitors and molecular targeted therapies are ongoing. Multidisciplinary approaches and further research are crucial for optimizing treatment and improving outcomes for advanced PC.

KEYWORDS: pancreatic cancer, multidisciplinary treatment, conversion surgery

Full Text: